Omnicell (NASDAQ:OMCL) Given New $44.00 Price Target at JPMorgan Chase & Co.

Omnicell (NASDAQ:OMCL) had its price target increased by JPMorgan Chase & Co. from $37.00 to $44.00 in a research note published on Thursday,Benzinga reports. The brokerage currently has a neutral rating on the stock.

A number of other analysts have also recently issued reports on OMCL. Benchmark reissued a “buy” rating and issued a $48.00 price objective on shares of Omnicell in a research note on Wednesday, October 9th. StockNews.com cut shares of Omnicell from a “buy” rating to a “hold” rating in a research note on Friday, November 15th. Bank of America reaffirmed a “neutral” rating and issued a $57.00 target price (up from $44.00) on shares of Omnicell in a report on Thursday, October 31st. Barclays increased their price target on Omnicell from $39.00 to $58.00 and gave the company an “equal weight” rating in a research note on Thursday, October 31st. Finally, Wells Fargo & Company increased their target price on Omnicell from $30.00 to $41.00 and gave the company an “equal weight” rating in a research report on Monday, October 14th. Five investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $52.00.

Omnicell Stock Up 3.6 %

NASDAQ:OMCL opened at $45.69 on Thursday. The firm has a market capitalization of $2.12 billion, a P/E ratio of -117.15, a P/E/G ratio of 37.10 and a beta of 0.81. Omnicell has a 52 week low of $25.12 and a 52 week high of $55.74. The company has a fifty day moving average of $44.27 and a 200 day moving average of $37.41.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Nisa Investment Advisors LLC lifted its position in shares of Omnicell by 248.8% during the second quarter. Nisa Investment Advisors LLC now owns 1,402 shares of the company’s stock valued at $38,000 after buying an additional 1,000 shares during the last quarter. GAMMA Investing LLC raised its position in Omnicell by 78.4% during the third quarter. GAMMA Investing LLC now owns 1,258 shares of the company’s stock valued at $55,000 after acquiring an additional 553 shares in the last quarter. EntryPoint Capital LLC lifted its holdings in Omnicell by 121.2% in the first quarter. EntryPoint Capital LLC now owns 2,455 shares of the company’s stock valued at $72,000 after acquiring an additional 1,345 shares during the period. CWM LLC boosted its position in Omnicell by 68.2% in the 2nd quarter. CWM LLC now owns 3,048 shares of the company’s stock worth $83,000 after purchasing an additional 1,236 shares in the last quarter. Finally, 1620 Investment Advisors Inc. lifted its stake in shares of Omnicell by 230.1% in the 3rd quarter. 1620 Investment Advisors Inc. now owns 2,212 shares of the company’s stock valued at $96,000 after purchasing an additional 1,542 shares during the period. Institutional investors own 97.70% of the company’s stock.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.